Our expert developers work with our health economists, medical writers and market access consultants to create Veeva‑compatible digital communication tools, including payer toolkits, budget impact models, and other data visualisations....
Read More
We understand that the path to successful global market access and uptake is complex and multi-faceted. Defining robust pricing and market access strategies, and developing meaningful value strategies, are essential...
Read More
We invited Pharma market access professionals to a seminar on 25th September 2019 at the Royal College of Physicians in London to hear directly from speakers who work in and...
Read More
Introducing David Thorne Director of NHS Insights & Interaction Originally a nurse, David has occupied board-level positions within both NHS hospitals and commissioning organisations. He was previously the Chief Executive...
Read More
Following the acquisition of Blue River Consulting we are pleased to announce that MD and owner David Thorne will be heading-up our NHS insights and interaction services at Mtech Access, bringing unparalleled hands-on experience and…
In order to comply with the EU regulation on medical devices, the regulatory stage Clinical Evaluation Report (CER) has been the focus of renewed attention by the medical device industry....
Read More
Partitioned survival analysis (PartSA) is currently the most commonly used modelling approach within HTA (health technology assessment) for advanced or metastatic cancers. However, until recently, there was no formal documentation...
Read More
A question I have been asked in the past is “Can you teach someone to be a consultant?” And the answer? Well, of course you can – but only up...
Read More
‘Time to event’ or ‘survival’ is an important endpoint used in efficacy assessments of medical interventions, particularly in disease areas such as oncology. The Cox proportional hazards (PH) model is…
Continuous outcomes data from trials may be categorised using pre-defined cut-offs to generate ordered categorical outcomes data. Usually the percentage of patients who have improved by certain thresholds are reported…
